Related Experiment Videos
The US experience with cilostazol in treating intermittent claudication.
1Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, University of Colorado, Health Sciences Center, Colorado Prevention Center, 789 Sherman Street, Suite 200, Denver, CO 80203, USA. Will.Hiatt@uchsc.edu
Atherosclerosis. Supplements
|November 9, 2005
Summary
Cilostazol is the leading FDA-approved medication for managing peripheral arterial disease (PAD) with intermittent claudication (IC), improving exercise capacity and quality of life. Comprehensive management strategies are recommended for PAD patients.
Area of Science:
- Vascular Medicine
- Pharmacology
Background:
- Peripheral arterial disease (PAD) with intermittent claudication (IC) necessitates robust risk management and symptomatic treatments.
- Current treatment options include risk-factor modification, exercise, revascularization, and pharmacotherapy.
Purpose of the Study:
- To review the role of cilostazol in treating IC in PAD patients.
- To evaluate the safety and efficacy of cilostazol compared to other therapies.
Main Methods:
- Review of clinical trial data on cilostazol's efficacy and safety.
- Analysis of evidence for risk-factor control, exercise, revascularization, and experimental drugs.
Main Results:
- Cilostazol is the only FDA-approved medication demonstrating consistent benefits in exercise capacity and quality of life for IC patients.
- Pentoxifylline is FDA-approved but offers less clinical benefit than cilostazol.
Conclusions:
- Cilostazol offers significant advantages for managing IC in PAD.
- A comprehensive, multi-modal approach is recommended for optimal claudication management.